Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.22

+1.01 (3.04%)

as of Jun 24, 2026, 8:00:00 pm Market Open.

69 watching

Investor Insights

Jun 24, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical, represented by the symbol TEVA-N, is currently experiencing a robust demand for GLP (glucose-lowering agents), although the entry of more generics may lead to price declines in this sector. The company has shown a remarkable recovery under its current CEO, boasting a 264% increase since January 2023, suggesting it's on a promising turnaround. Its headquarters are located in Israel, and it holds a strong position as a large-cap pharmaceutical company, ranking #1 in its ADR/CDR universe among international stocks. Following a breakout over $21 in September, Teva has seen significant accumulation over the past six months, although it does not pay dividends. Analysts remain optimistic, with a price target of $34.50.

Consensus

positive

Valuation

undervalued

Similar

Roche, RHHBY

PAST TOP PICK

(Was a top pick on Jan 25/01 up 11%) Still likes, but may be fully valued now.

PAST TOP PICK

(Was a top pick on Aug 3/00 up 1.3%) Still likes and still buying.

BUY

Likes the generic drug sector as patent expirations are coming. Global. Good cash flow

TOP PICK

World's largest generic drug company. Good distribution. Patents are going off now so generics are prospering.

BUY

Likes the generic drug space. Govts will be pressured for lower health costs. Prefers this over Biovale

Showing 271 to 275 of 275 entries

Most Recent Experts

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Harris Douglas Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)